Story March 20 - Elevation Oncology: The biotech is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data and laying off 70% of its staff as a result. The restructuring ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

当地时间4月15日，Mural Oncology宣布终止其新型免疫疗法nemvaleukin的所有临床开发计划，并裁员90%。该决定是在对黑色素瘤II期ARTISTRY-6研究和铂耐药卵巢癌III期ARTISTRY-7研究数据进行评估后做出的。尽管这一壮举似乎相当反常，但Mural的股价却强劲上涨，收盘时飙升134%至4152.01万美元。

The approach is an ultrasound-based technique that offers a pain-free alternative. Singapore’s oncology field is set for a ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

The layoffs come as the biotech industry struggles. The post Mass. biotech company cuts 90% of workforce appeared first on Boston.com.

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc. (NASDAQ:CRDF) stands against other hot biotech stocks ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc ... Abid brings over 20 years of experience in the biotechnology sector with expertise in financial strategy and corporate ...